Does the media refer more to PRTA or VIR?

In the previous week, Vir Biotechnology had 2 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Vir Biotechnology and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Vir Biotechnology's score of 1.27 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vir Biotechnology 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRTA or KLRA?

In the previous week, Kailera Therapeutics had 8 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Kailera Therapeutics and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Kailera Therapeutics' score of 0.13 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kailera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRTA or RXRX?

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Recursion Pharmaceuticals' score of 0.44 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Recursion Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRTA or DMRA?

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Damora Therapeutics, Inc. Common Stock's score of 0.51 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prothena (PRTA) Competitors

$8.33 -0.13 (-1.54%)

As of 11:27 AM Eastern

Compare

PRTA vs. VIR, KLRA, RXRX, DMRA, and FBRX

Should you buy Prothena stock or one of its competitors? Prothena's main competitors and comparable companies include Vir Biotechnology (VIR), Kailera Therapeutics (KLRA), Recursion Pharmaceuticals (RXRX), Damora Therapeutics, Inc. Common Stock (DMRA), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prothena compare to Vir Biotechnology?

Prothena (NASDAQ:PRTA) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prothena presently has a consensus target price of $24.57, suggesting a potential upside of 194.98%. Vir Biotechnology has a consensus target price of $21.57, suggesting a potential upside of 102.57%. Given Prothena's higher possible upside, research analysts clearly believe Prothena is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Prothena has a net margin of -80.68% compared to Vir Biotechnology's net margin of -638.88%. Prothena's return on equity of -16.45% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Prothena has a beta of -0.33, meaning that its stock price is 133% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

In the previous week, Vir Biotechnology had 2 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Vir Biotechnology and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Vir Biotechnology's score of 1.27 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vir Biotechnology	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prothena has higher earnings, but lower revenue than Vir Biotechnology. Prothena is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.05	-$244.09M	-$0.84	N/A
Vir Biotechnology	$302.59M	5.96	-$437.99M	-$1.86	N/A

Summary

Prothena beats Vir Biotechnology on 10 of the 16 factors compared between the two stocks.

How does Prothena compare to Kailera Therapeutics?

Prothena (NASDAQ:PRTA) and Kailera Therapeutics (NASDAQ:KLRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Kailera Therapeutics has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.05	-$244.09M	-$0.84	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kailera Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Kailera Therapeutics' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Kailera Therapeutics	N/A	N/A	N/A

In the previous week, Kailera Therapeutics had 8 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Kailera Therapeutics and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Kailera Therapeutics' score of 0.13 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kailera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prothena currently has a consensus target price of $24.57, suggesting a potential upside of 194.98%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 243.65%. Given Kailera Therapeutics' higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Kailera Therapeutics beats Prothena on 7 of the 12 factors compared between the two stocks.

How does Prothena compare to Recursion Pharmaceuticals?

Prothena (NASDAQ:PRTA) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

97.1% of Prothena shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Prothena currently has a consensus price target of $24.57, suggesting a potential upside of 194.98%. Recursion Pharmaceuticals has a consensus price target of $8.06, suggesting a potential upside of 120.52%. Given Prothena's stronger consensus rating and higher probable upside, equities analysts plainly believe Prothena is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Prothena has higher earnings, but lower revenue than Recursion Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.05	-$244.09M	-$0.84	N/A
Recursion Pharmaceuticals	$53.94M	36.28	-$644.76M	-$1.04	N/A

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Recursion Pharmaceuticals' score of 0.44 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prothena has a net margin of -80.68% compared to Recursion Pharmaceuticals' net margin of -945.94%. Prothena's return on equity of -16.45% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Prothena has a beta of -0.33, indicating that its stock price is 133% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Summary

Prothena beats Recursion Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Prothena compare to Damora Therapeutics, Inc. Common Stock?

Prothena (NASDAQ:PRTA) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

97.1% of Prothena shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Prothena. Prothena's average media sentiment score of 1.87 beat Damora Therapeutics, Inc. Common Stock's score of 0.51 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Damora Therapeutics, Inc. Common Stock has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.05	-$244.09M	-$0.84	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

Prothena presently has a consensus target price of $24.57, suggesting a potential upside of 194.98%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $44.00, suggesting a potential upside of 89.74%. Given Prothena's higher possible upside, analysts clearly believe Prothena is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

Prothena has a beta of -0.33, suggesting that its stock price is 133% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Summary

Prothena and Damora Therapeutics, Inc. Common Stock tied by winning 8 of the 16 factors compared between the two stocks.

How does Prothena compare to Forte Biosciences?

Prothena (NASDAQ:PRTA) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Forte Biosciences has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Forte Biosciences	N/A	-94.82%	-77.68%

Prothena presently has a consensus price target of $24.57, indicating a potential upside of 194.98%. Forte Biosciences has a consensus price target of $71.67, indicating a potential downside of 6.91%. Given Prothena's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prothena is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

97.1% of Prothena shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Forte Biosciences has lower revenue, but higher earnings than Prothena. Forte Biosciences is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.05	-$244.09M	-$0.84	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

In the previous week, Prothena had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 1 mentions for Prothena and 0 mentions for Forte Biosciences. Prothena's average media sentiment score of 1.87 beat Forte Biosciences' score of 0.00 indicating that Prothena is being referred to more favorably in the media.

Company	Overall Sentiment
Prothena	Very Positive
Forte Biosciences	Neutral

Prothena has a beta of -0.33, suggesting that its share price is 133% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market.

Summary

Prothena beats Forte Biosciences on 13 of the 16 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTA vs. The Competition

Export

Metric	Prothena	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$436.08M	$3.88B	$7.20B	$13.99B
Dividend Yield	N/A	3.65%	2.57%	12.64%
P/E Ratio	-9.92	14.02	274.36	25.47
Price / Sales	45.05	1,544.64	684.04	100.00
Price / Cash	N/A	109.14	77.01	51.20
Price / Book	1.60	15.44	10.47	6.28
Net Income	-$244.09M	-$22.78M	$3.48B	$358.12M
7 Day Performance	-6.72%	-1.10%	0.94%	1.24%
1 Month Performance	-4.36%	-1.58%	-0.03%	-2.10%
1 Year Performance	1.83%	35.91%	18.28%	5.07%

Prothena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTA Prothena	3.4889 of 5 stars	$8.33 -1.5%	$24.57 +195.0%	+5.0%	$436.08M	$9.68M	N/A	67	Positive News
VIR Vir Biotechnology	1.8837 of 5 stars	$10.27 -4.6%	$21.57 +110.0%	+127.5%	$1.74B	$302.59M	N/A	367	Positive News
KLRA Kailera Therapeutics	3.156 of 5 stars	$13.39 -2.6%	$42.75 +219.3%	N/A	$1.74B	N/A	N/A	145	Gap Up
RXRX Recursion Pharmaceuticals	1.5821 of 5 stars	$3.24 -5.1%	$8.06 +149.1%	-24.8%	$1.73B	$53.94M	N/A	600	News Coverage Options Volume
DMRA Damora Therapeutics, Inc. Common Stock	2.7196 of 5 stars	$26.65 -6.1%	$44.00 +65.1%	+699.3%	$1.65B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTA) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Competitors

PRTA vs. VIR, KLRA, RXRX, DMRA, and FBRX

How does Prothena compare to Vir Biotechnology?

Summary

How does Prothena compare to Kailera Therapeutics?

Summary

How does Prothena compare to Recursion Pharmaceuticals?

Summary

How does Prothena compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Prothena compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Competitors

PRTA vs. VIR, KLRA, RXRX, DMRA, and FBRX

How does Prothena compare to Vir Biotechnology?

Do insiders & institutionals hold more shares of PRTA or VIR?

Do analysts rate PRTA or VIR?

Is PRTA or VIR more profitable?

Which has more risk and volatility, PRTA or VIR?

Does the media refer more to PRTA or VIR?

Which has preferable valuation & earnings, PRTA or VIR?

Summary

How does Prothena compare to Kailera Therapeutics?

Which has preferable earnings & valuation, PRTA or KLRA?

Do institutionals and insiders hold more shares of PRTA or KLRA?

Is PRTA or KLRA more profitable?

Does the media favor PRTA or KLRA?

Do analysts prefer PRTA or KLRA?

Summary

How does Prothena compare to Recursion Pharmaceuticals?

Do institutionals and insiders believe in PRTA or RXRX?

Do analysts rate PRTA or RXRX?

Which has higher earnings and valuation, PRTA or RXRX?

Does the media favor PRTA or RXRX?

Is PRTA or RXRX more profitable?

Which has more risk & volatility, PRTA or RXRX?

Summary

How does Prothena compare to Damora Therapeutics, Inc. Common Stock?

Do institutionals and insiders believe in PRTA or DMRA?

Does the media refer more to PRTA or DMRA?

Which has preferable valuation & earnings, PRTA or DMRA?

Do analysts prefer PRTA or DMRA?

Is PRTA or DMRA more profitable?

Which has more volatility & risk, PRTA or DMRA?

Summary

How does Prothena compare to Forte Biosciences?

Is PRTA or FBRX more profitable?

Do analysts rate PRTA or FBRX?

Do institutionals and insiders have more ownership in PRTA or FBRX?

Which has higher earnings and valuation, PRTA or FBRX?

Does the media refer more to PRTA or FBRX?

Which has more volatility & risk, PRTA or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools